Source link : https://newshealth.biz/health-news/upfront-ivonescimab-plus-chemo-bests-pd-1-inhibitor-combo-in-advanced-nsclc/
CHICAGO — A first-in-class bispecific antibody targeting PD-1 and VEGF combined with chemotherapy significantly improved overall survival (OS) in patients with advanced squamous non-small cell lung cancer (NSCLC), according to the HARMONi-6 trial. At a median follow-up of 21.4 months, the ivonescimab-chemotherapy combination in the first line reduced the risk of death by 34%, with […]
The post Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-31 19:57:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8